Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant Escherichia coli Strains in a Hollow-Fiber Infection Model

We evaluated human-like the efficacy of intravenous doses of fosfomycin of 8 g every 8 h (8 g/Q8h) and of amikacin (15 mg/kg/Q24h) in monotherapy and in combination against six fosfomycin-heteroresistant Escherichia coli isolates using a hollow-fiber infection model (HFIM). Six fosfomycin-heteroresi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Portillo-Calderón, I., Ortiz-Padilla, M., de Gregorio-Iaria, B., Merino-Bohorquez, V., Blázquez, J., Rodríguez-Baño, J., Rodríguez-Martínez, J. M., Pascual, A., Docobo-Pérez, F.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2021
Matèries:
Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8092889/
https://ncbi.nlm.nih.gov/pubmed/33685903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02213-20
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars